3 June 2025 · 1 min read

The FDA now uses GenAI to review your dossier - and that's a good thing.

The FDA is now using GenAI to review regulatory dossiers — and I think that's a good thing. Pharma companies have already been using generative AI to craft submissions, so it makes perfect sense for regulators to leverage the same technology on their end.

Author

Christian Hein

Last updated

6 May 2026

Generative AI Regulatory / Compliance Large Pharma Artificial Intelligence Innovation Management Clinical development

The FDA now uses GenAI to review your dossier - and that's a good thing.

Why? Because pharma companies have already been harnessing generative AI to craft clinical trial designs, draft protocols, and streamline regulatory submissions. It makes perfect sense that regulatory authorities leverage similar tech for review processes, ensuring alignment and efficiency.

Now, with the FDA integrating its own AI, we're entering a fascinating new era: where AI-optimized submissions meet AI-powered reviews. Watching how this dynamic evolves in the coming years will be very interesting.